These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 15362663

  • 1. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).
    Breilh D, Pellegrin I, Rouzés A, Berthoin K, Xuereb F, Budzinski H, Munck M, Fleury HJ, Saux MC, Pellegrin JL.
    AIDS; 2004 Jun 18; 18(9):1305-10. PubMed ID: 15362663
    [Abstract] [Full Text] [Related]

  • 2. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Lazzarin A, Castagna A.
    J Med Virol; 2006 Dec 18; 78(12):1537-41. PubMed ID: 17063520
    [Abstract] [Full Text] [Related]

  • 3. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
    Pellegrin I, Wittkop L, Joubert LM, Neau D, Bollens D, Bonarek M, Girard PM, Fleury H, Winters B, Saux MC, Pellegrin JL, Thiébaut R, Breilh D, ANRS Co3 Aquitaine Cohort.
    Antivir Ther; 2008 Dec 18; 13(2):271-9. PubMed ID: 18505178
    [Abstract] [Full Text] [Related]

  • 4. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.
    J Clin Virol; 2007 Feb 18; 38(2):131-8. PubMed ID: 17208042
    [Abstract] [Full Text] [Related]

  • 5. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
    Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R, Sun E.
    Antivir Ther; 2002 Sep 18; 7(3):165-74. PubMed ID: 12487383
    [Abstract] [Full Text] [Related]

  • 6. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G, Chêne G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM, Puzzle 1 Study Group.
    Antivir Ther; 2004 Aug 18; 9(4):615-25. PubMed ID: 15456093
    [Abstract] [Full Text] [Related]

  • 7. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient.
    González de Requena D, Gallego O, Valer L, Jiménez-Nácher I, Soriano V.
    AIDS Res Hum Retroviruses; 2004 Mar 18; 20(3):275-8. PubMed ID: 15117450
    [Abstract] [Full Text] [Related]

  • 8. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients.
    Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, Lamotte C, Schneider V, Ritter J, Segondy M, Peigue-Lafeuille H, Morand-Joubert L, Schmuck A, Ruffault A, Palmer P, Chaix ML, Mackiewicz V, Brodard V, Izopet J, Cottalorda J, Kohli E, Chauvin JP, Kempf DJ, Peytavin G, Calvez V.
    Antimicrob Agents Chemother; 2005 May 18; 49(5):1720-6. PubMed ID: 15855487
    [Abstract] [Full Text] [Related]

  • 9. Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.
    von Hentig N, Babacan E, Staszewski S, Stürmer M, Doerr HW, Lötsch J.
    Antivir Ther; 2007 May 18; 12(8):1237-46. PubMed ID: 18240863
    [Abstract] [Full Text] [Related]

  • 10. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
    Pellegrin I, Breilh D, Montestruc F, Caumont A, Garrigue I, Morlat P, Le Camus C, Saux MC, Fleury HJ, Pellegrin JL.
    AIDS; 2002 Jul 05; 16(10):1331-40. PubMed ID: 12131209
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
    Loutfy MR, Raboud JM, Walmsley SL, Saskin R, Montaner JS, Hogg RS, Thompson CA, Harrigan PR.
    Antivir Ther; 2004 Aug 05; 9(4):595-602. PubMed ID: 15456091
    [Abstract] [Full Text] [Related]

  • 12. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I, Breilh D, Ragnaud JM, Boucher S, Neau D, Fleury H, Schrive MH, Saux MC, Pellegrin JL, Lazaro E, Vray M.
    Antivir Ther; 2006 Aug 05; 11(4):421-9. PubMed ID: 16856615
    [Abstract] [Full Text] [Related]

  • 13. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
    Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ, GARDEL Study Group.
    Lancet Infect Dis; 2014 Jul 05; 14(7):572-80. PubMed ID: 24783988
    [Abstract] [Full Text] [Related]

  • 14. The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lopinavir/ritonavir-containing regimen.
    Castagna A, Gianotti N, Galli L, Danise A, Hasson H, Boeri E, Hoetelmans R, Nauwelaers D, Lazzarin A.
    Antivir Ther; 2004 Aug 05; 9(4):537-43. PubMed ID: 15456085
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M.
    Scand J Infect Dis; 2004 Aug 05; 36(11-12):823-8. PubMed ID: 15764168
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.
    Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E, Spanish Collaborative Group on HIV Infection in Children.
    Pediatr Infect Dis J; 2005 Oct 05; 24(10):867-73. PubMed ID: 16220083
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.